Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease
Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease
复制标题
DOI：
10.1002/cbf.980
复制
发表时间：
2002-12-01
影响因子：
3.6
通讯作者：
Erdogan, F
中科院分区：
文献类型：
--
作者：
Polat, MF;Taysi, S;Erdogan, F
本研究的目的是调查恶性乳腺肿瘤和良性乳腺疾病患者血液中脂质过氧化和抗氧化酶防御的变化。该研究招募了 40 名恶性乳腺肿瘤患者、20 名良性乳腺疾病患者以及 20 名健康对照受试者。测定血浆和红细胞中的丙二醛水平，以及红细胞铜锌超氧化物歧化酶、过氧化氢酶、谷胱甘肽过氧化物酶和葡萄糖-6-磷酸脱氢酶的活性。与对照组相比，良性乳腺疾病和恶性乳腺肿瘤患者的丙二醛水平较高。乳腺恶性肿瘤患者所有抗氧化酶活性均较高，而乳腺良性疾病患者仅谷胱甘肽过氧化物酶和铜锌超氧化物歧化酶活性较高。除葡萄糖-6-磷酸脱氢酶外，研究的抗氧化酶与恶性乳腺肿瘤患者的丙二醛水平呈正相关。另一方面，只有葡萄糖-6-磷酸脱氢酶活性随着恶性肿瘤的水平而增加。红细胞抗氧化酶活性的增加可能是对氧化应激增加的补偿性上调，尤其是在患有恶性乳腺肿瘤的患者中。版权所有 (C) 2002 John Wiley Sons, Ltd.
The aim of this study was to investigate the alterations in lipid peroxidation and antioxidant enzyme defences in the blood of patients with malignant breast tumour and benign breast disease. Forty patients with malignant breast tumour, 20 patients with benign breast disease and also 20 healthy control subjects were recruited for the study. Malondialdehyde levels in plasma and erythrocytes, and the activities of erythrocyte CuZn-superoxide dismutase, catalase, glutathione peroxidase and glucose-6-phosphate dehydrogenase were measured. Malondialdehyde levels were higher in patients with both benign breast disease and malignant breast tumour compared with control subjects. The activities of all antioxidant enzymes were higher in patients with malignant breast tumour, while only glutathione peroxidase and CuZn-superoxide dismutase activities were higher in patients with benign breast disease. Except for glucose-6-phosphate dehydrogenase, the antioxidant enzymes studied correlated positively with the malondialdehyde levels in patients with malignant breast tumour. On the other hand, only glucose-6-phosphate dehydrogenase activity was increased by the level of malignancy. The activity increases in erythrocyte antioxidant enzymes may be a compensatory upregulation in response to increased oxidative stress especially in patients with malignant breast tumour. Copyright (C) 2002 John Wiley Sons, Ltd.